BACKGROUND: The incidence of hepatocellular carcinoma (HCC) is increasing, but surgical management continues to be underutilized. This retrospective review investigates treatment decisions and survival for early stage HCC. METHODS: The National Cancer Database (NCDB) was queried for all patients with curable HCC (Stage I/II) from 1998 to 2011 (n = 43 859). Patient and tumour characteristics were analysed to determine predictors of having surgery and of long-term survival. RESULTS: Only 39.7% of patients received surgery for early stage HCC. Surgical therapies included resection (34.6%), transplant (28.7%), radiofrequency ablation (27.1%) and other therapies. Surgery correlated with improved median survival (48.3 versus 8.4 months), but was only performed on 42% of stage I patients and 50% of tumours smaller than 2 cm. Patients were more likely to receive surgery if they were Asian or white race, had private insurance, higher income, better education, or treatment at an academic centre (P < 0.05). However, private insurance and treatment at an academic centre were the only variables associated with improved survival (P < 0.05). CONCLUSION: Fewer than half of patients with curable HCC receive surgery, possibly as a result of multiple socioeconomic variables. Past these barriers to care, survival is related to adequate and reliable treatment. Further efforts should address these disparities in treatment decisions.
BACKGROUND: The incidence of hepatocellular carcinoma (HCC) is increasing, but surgical management continues to be underutilized. This retrospective review investigates treatment decisions and survival for early stage HCC. METHODS: The National Cancer Database (NCDB) was queried for all patients with curable HCC (Stage I/II) from 1998 to 2011 (n = 43 859). Patient and tumour characteristics were analysed to determine predictors of having surgery and of long-term survival. RESULTS: Only 39.7% of patients received surgery for early stage HCC. Surgical therapies included resection (34.6%), transplant (28.7%), radiofrequency ablation (27.1%) and other therapies. Surgery correlated with improved median survival (48.3 versus 8.4 months), but was only performed on 42% of stage I patients and 50% of tumours smaller than 2 cm. Patients were more likely to receive surgery if they were Asian or white race, had private insurance, higher income, better education, or treatment at an academic centre (P < 0.05). However, private insurance and treatment at an academic centre were the only variables associated with improved survival (P < 0.05). CONCLUSION: Fewer than half of patients with curable HCC receive surgery, possibly as a result of multiple socioeconomic variables. Past these barriers to care, survival is related to adequate and reliable treatment. Further efforts should address these disparities in treatment decisions.
Authors: Hari Nathan; Dorry L Segev; John F P Bridges; Allan B Massie; Andrew M Cameron; Kenzo Hirose; Richard D Schulick; Michael A Choti; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2012-09-01 Impact factor: 5.344
Authors: Jeanette C Yu; Alfred I Neugut; Shuang Wang; Judith S Jacobson; Lauren Ferrante; Vandana Khungar; Emerson Lim; Dawn L Hershman; Robert S Brown; Abby B Siegel Journal: Cancer Date: 2010-04-01 Impact factor: 6.860
Authors: Victor Zaydfudim; Martin A Whiteside; Marie R Griffin; Irene D Feurer; J Kelly Wright; C Wright Pinson Journal: Ann Surg Oncol Date: 2010-06-29 Impact factor: 5.344
Authors: Amy Anne D Lassig; Anne M Joseph; Bruce R Lindgren; Patricia Fernandes; Sarah Cooper; Chelsea Schotzko; Samir Khariwala; Margaret Reynolds; Bevan Yueh Journal: Otolaryngol Head Neck Surg Date: 2012-08-08 Impact factor: 3.497
Authors: Shimul A Shah; Jillian K Smith; Youfu Li; Sing Chau Ng; James E Carroll; Jennifer F Tseng Journal: Cancer Date: 2010-10-13 Impact factor: 6.860
Authors: Rittal Mehta; Kota Sahara; Katiuscha Merath; J Madison Hyer; Diamantis I Tsilimigras; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Mary Dillhoff; Allan Tsung; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2019-06-13 Impact factor: 3.452
Authors: Patricio M Polanco; Michelle R Ju; Matthieu Chansard; M Mathew Augustine; Jennie Meier; Eric Mortensen; Herbert J Zeh; Adam C Yopp Journal: Ann Surg Oncol Date: 2022-05-22 Impact factor: 4.339
Authors: Shoshana Adler Jaffe; Orrin Myers; Angela L W Meisner; Charles L Wiggins; Deirdre A Hill; Jean A McDougall Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-12-03 Impact factor: 4.254
Authors: Joshua P Kronenfeld; Emily L Ryon; David Goldberg; Rachel M Lee; Adam Yopp; Annie Wang; Ann Y Lee; Sommer Luu; Cary Hsu; Eric Silberfein; Maria C Russell; Nipun B Merchant; Neha Goel Journal: HPB (Oxford) Date: 2020-12-29 Impact factor: 3.842